The overall goal of the Pharmacology and Analytical Center Facility is to provide the broad base of sophistical analytical equipment and expertise in pharmacology and medicinal chemistry required for preclinical and clinical investigations of anti-cancer drugs and related therapies. This goal will be accomplished by focusing on three aims. First, the Pharmacology and Analytical Center Facility will enable expanded analytical support for basic and clinical scientists at The University of Texas M.D. Anderson Cancer Center. This support will include access to instruments for nuclear magnetic resonance (NMR), liquid chromatography (LC)/mass spectrometry (MS), gas chromatography (GC), GC/MS, and high- performance liquid chromatography (HPLC). Support will also include assistance with the verification of structural identify, purification, and determination of stability of drugs and drug metabolites, as well as assistance with developing assays, solving proof-of-identity problems, and developing validation procedures. Second, scientists running the Pharmacology and Analytical Center Facility will provide a resource for investigators seeking pharmacokinetic and pharmacodynamic information on specific compounds and knowledge off how to best use such information for optimal protocol design, dose adjustments to increase efficacy or decrease toxicity, and similar clinical problems. Finally, the Pharmacology and Analytical Center Facility will provide a pharmacology resource for information about and techniques for studying nucleic acid components, such as bases, nucleosides, nucleotides, and oligonucleotides. This services will also include quantitation of the radioactivity associated with proteins, and Betascope and radiometric flow analytical instrumentation will be available. The analytical instruments of the Pharmacology and Analytical Center Facility are conveniently housed on the same (seventh) floor of M.D. Anderson Cancer Center in laboratories run by Director Robert Newman and co-directors William Plunkett, Timothy Madden, and David Farquhar. The equipment and analytical support to be provided by the facility are deemed critical for the success of many of the disease site- and them-specific programs proposed in this application. Formation of the Pharmacology and Analytical Center Facility will augment the ability of M.D. Anderson investigators to collaborate on studies involving pharmacologic analyses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-25S1
Application #
6347276
Study Section
Project Start
2000-08-30
Project End
2001-06-30
Budget Start
Budget End
Support Year
25
Fiscal Year
2000
Total Cost
$254,104
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Bose, Prithviraj; Gotlib, Jason; Harrison, Claire N et al. (2018) SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk 18:1-12
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :
Huang, Shengjian; Jiang, Changying; Zhang, Hui et al. (2018) The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma. Blood Cancer J 8:33
Hwang, Jessica P; Ahmed, Sairah; Ariza-Heredia, Ella J et al. (2018) Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. Biol Blood Marrow Transplant 24:1094-1098
He, Jing; Huo, Lei; Ma, Junsheng et al. (2018) Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol 149:253-261
Schembre, Susan M; Liao, Yue; O'Connor, Sydney G et al. (2018) Mobile Ecological Momentary Diet Assessment Methods for Behavioral Research: Systematic Review. JMIR Mhealth Uhealth 6:e11170
Abbas, Hussein A; Bui, Ngoc Hoang Bao; Rajapakshe, Kimal et al. (2018) Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. Cancer Res 78:451-462
Zhu, Lele; Xie, Xiaoping; Zhang, Lingyun et al. (2018) TBK-binding protein 1 regulates IL-15-induced autophagy and NKT cell survival. Nat Commun 9:2812
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :

Showing the most recent 10 out of 12418 publications